Conflict of interest The BIOBADADERM project is financed by the Spanish Academy of Dermatology and Sexually-Transmitted Diseases Foundation, which is financed by the Spanish Medicines and Health Products Agency. In addition, it receives similar financial support from pharmaceutical companies (Abbott, Pfizer and Janssen). Collaborating pharmaceutical companies have not participated in the analysis or interpretation of the data.
Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate–severe psoriasis in Spain. BIOBADADERM registry
Article first published online: 8 NOV 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 11, pages 1366–1374, November 2013
How to Cite
Sánchez-Moya, A.I., García-Doval, I., Carretero, G., Sánchez-Carazo, J., Ferrandiz, C., Herrera Ceballos, E., Alsina, M., Ferrán, M., López-Estebaranz, J.-L., Gómez-García, F., De la Cueva Dobao, P., Carrascosa, J.-M., Vanaclocha, F., Belinchón, I., Peral, F., Dauden, E. and the BIOBADADERM Study Group (2013), Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate–severe psoriasis in Spain. BIOBADADERM registry. Journal of the European Academy of Dermatology and Venereology, 27: 1366–1374. doi: 10.1111/jdv.12011
- Issue published online: 16 OCT 2013
- Article first published online: 8 NOV 2012
- Received: 30 April 2012; Accepted: 19 September 2012
Introduction The incidence of tuberculosis (TB) or the prevalence of latent tuberculosis infection (LTBI) in psoriasis patients has not been described in the Spanish population. We carried out a study with the objectives: (i) To describe the incidence of TB in patients with psoriasis on systemic treatment in the Spanish population; (ii) To determine the prevalence of LTBI in patients who are candidates for biological treatment; and (iii) To investigate the level of compliance with current recommendations for LTBI and TB screening.
Methods Data were obtained from BIOBADADERM (Spanish registry for systemic biological and non-biological treatments in psoriasis). An analysis was performed of the exposed cohort to determine the prevalence of LTBI and to describe compliance with the screening guidelines.
Results A total of 1425 patients were registered in BIOBADADERM. They included 793 (56%) patients exposed to biological treatment and 632 (44%) treated with conventional systemic drug. Overall follow-up was 3720 person-years. Of the 793, 20.5% (163) were diagnosed with LTBI before starting biological treatment. The rate of active TB for the exposed cohort was 145 cases × 100 000 patient-years (95% CI 54–389). No case of TB was found in the control group. Screening for LTBI was performed in 83% of the exposed sample.
Conclusion Patients with psoriasis who are exposed to biological treatment appear to be at greater risk for tuberculosis. In Spain, up to 20% of patients with psoriasis who are candidates for biological therapy have LTBI. There continues to be a significant percentage of errors in compliance with clinical guidelines.